Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$9 Mln
P/E Ratio
--
P/B Ratio
0.14
Industry P/E
--
Debt to Equity
0
ROE
-0.52 %
ROCE
--
Div. Yield
0 %
Book Value
8.47
EPS
-5.87
CFO
$-138.80 Mln
EBITDA
$-158.57 Mln
Net Profit
$-157.95 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Citius Pharmaceuticals (CTXR)
| -75.80 | -35.47 | -70.31 | -94.84 | -70.77 | -43.65 | -44.90 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Citius Pharmaceuticals (CTXR)
| -78.59 | -4.18 | -48.70 | 50.98 | 0.00 | -1.92 | -72.44 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.... The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Address: 11 Commerce Drive, Cranford, NJ, United States, 07016 Read more
Co-Founder, CEO, Chairman & Secretary
Mr. Leonard L. Mazur
Co-Founder, CEO, Chairman & Secretary
Mr. Leonard L. Mazur
Headquarters
Cranford, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Citius Pharmaceuticals Inc (CTXR) stood at $ 166 Mln as on 31-Dec-24
The share price of Citius Pharmaceuticals Inc (CTXR) is $0.97 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Citius Pharmaceuticals Inc (CTXR) has given a return of -70.77% in the last 3 years.
Citius Pharmaceuticals Inc (CTXR) has a market capitalisation of $ 9 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Citius Pharmaceuticals Inc (CTXR) is 0.14 times as on 17-Apr-2025, a 94% discount to its peers’ median range of 2.26 times.
Since, TTM earnings of Citius Pharmaceuticals Inc (CTXR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Citius Pharmaceuticals Inc (CTXR) and enter the required number of quantities and click on buy to purchase the shares of Citius Pharmaceuticals Inc (CTXR).
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Address: 11 Commerce Drive, Cranford, NJ, United States, 07016
The CEO & director of Mr. Leonard L. Mazur. is Citius Pharmaceuticals Inc (CTXR), and CFO & Sr. VP is Mr. Leonard L. Mazur.
There is no promoter pledging in Citius Pharmaceuticals Inc (CTXR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Citius Pharmaceuticals Inc. (CTXR) | Ratios |
|---|---|
|
Return on equity(%)
|
-51.84
|
|
Operating margin(%)
|
-27414.26
|
|
Net Margin(%)
|
-25445.34
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Citius Pharmaceuticals Inc (CTXR) was $0 Mln.
$-0.02
(
